Initial trials indicate that the compound – a dual activator of incretin and glucose-dependent insulinotropic polypeptide receptors – may provide a considerable improvement in body loss therapies. Unlike existing treatments , this dual-action compound shows to modify hunger and metabolic expenditure by means of separate routes. While additiona